WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 33'7631 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 47'066  46'927  46'755  46'514  46'182  40'283  38'883  37'493 
Births 481  488  493  496  496  397  395  575 
Surviving infants 480  486  491  494  495  395  392  567 
Pop. less than 5 years 2'503  2'530  2'545  2'543  2'521  1'865  2'055  3'134 
Pop. less than 15 years 7'273  7'205  7'119  7'015  6'894  5'953  7'729  9'739 
Female 15-49 years 10'932  11'063  11'185  11'285  11'354  10'435  9'672  8'849 

Number of reported case

(Click for retrospective incidence data for Spain)
Diphtheria
Japanese encephalitis
Measles 154  131  1'204  3'802  302  152  21'650  145'322 
Mumps 13'951  9'539  4'416  2'516  9'391 
Pertussis 2'342  3'439  3'088  739  921  10'075 
Polio* 17 
Rubella 64  30  345 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 13  12  27  54  500 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Spain)
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          97  96  97  97  97  95  86 
DTP4          95 
IPV1         
HepB_BD         
HepB3          96  95  96  97  97  77 
Hib3          97  96  97  97  97  92 
JapEnc         
MCV1          96  95  97  97  95  94  99 
MCV2          93  91  90  91  92 
PCV1         
PCV3         
Pol3          97  96  97  97  97  95  94 
Rota1         
Rota_last         
Rubella1          96  95  97  95 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Spain)
DTP1 99  98  99  99  99  98  95 
DTP3 97  96  97  97  97  95  86 
HepB3 96  95  96  97  97  77 
HepB_BD
Hib3 96  96  97  97  97  92 
MCV1 96  95  97  97  95  94  99 
MCV2 93  91  90  91  92 
PCV3
Pol3 97  96  97  97  97  95  94 
Rota_last

Number of districts in the country 19  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 6 months; Yes
DTaPHibIPV 4, 18 months; Yes
HPV 12 years (x3); Yes
HepA Yes risk groups
HepB_Adult risk groups
HepB_Pediatric birth; Yes
Influenza_Adult >= 65 years; Yes and pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 12 months; 3-4 years; Yes
MenC_conj 2,4 months;12 years; Yes
Pneumo_ps > 64 years; and risk groups
Td 14 years; Yes
Tdap 6 years; Yes
Varicella 12 years (x2); Yes susceptible adolescents only

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  NA  NA  NA  NA  NA  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 19  19  19  19  19  19  19 
Nº districts with DTP3 coverage >=80% number 19  19  19  17  18  15  15 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  89  95  79  79 
Nº districts with measles (MCV1) coverage >=95% number 16  15  15  15  16  15  15 
% of districts with MCV1 coverage >=95% From 0 to 100% 84  79  79  79  84  79  79 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%       100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.